Background Emotional stress is associated with increased risk of cardiovascular disease. We imaged the amygdala, a brain region involved in stress, to determine whether its resting metabolic activity predicts risk of subsequent cardiovascular events.
Introduction
Psychosocial stress is both a byproduct of adversity and an important precipitant of morbidity. Chronic stress is associated with an increased risk of cardiovascular disease, 1, 2 with an attributable risk that is on par with that of other major cardiovascular risk factors. [3] [4] [5] However, little is known about the mechanisms that translate stress into cardiovascular events.
Although several factors could account for the risk of cardiovascular disease attributable to stress, the brain's salience network, an ensemble of interconnected structures involved in complex functions such as cognition and emotion, is thought to have an important role. Activation of this network, which includes the amygdala as a key component, 6 leads to hormonal, autonomic, and behavioural changes typically associated with fear and stress. 7 The amygdala's eff erent projections to the brainstem participate in the sympathetic responses to stress. 8 In murine models, stress increases proliferation of haemopoietic stem cells and progenitor cells in the bone marrow, accelerates innate immune cell output and cytokine production, and potentiates atherosclerosis. [9] [10] [11] [12] [13] However, whether a homologous path way exists in human beings is unknown. Furthermore, although amygdalar reactivity is known to be heightened in individuals with pre-existing atherosclerosis, 14 neither human nor animal studies have yet shown whether amygdalar activation precedes and predisposes to the subsequent development of cardiovascular events.
Activation of the neural circuitry underlying the perception of fear-related stimuli can be reproducibly imaged using functional MRI (fMRI) and ¹⁸F-fl uoro deoxyglucose (¹⁸F-FDG) PET/CT. 15, 16 Amygdalar activity is upregulated in conditions marked by stress, such as post-traumatic stress disorder, anxiety, and depression. [16] [17] [18] [19] [20] By showing cellular glycolysis, ¹⁸F-FDG PET/CT can be used to simultaneously quantify not only regional brain metabolism (activity), [16] [17] [18] [19] 21 but also haemopoietic tissue activity and large vessel arterial infl ammation, 12, 22 thereby making it uniquely suitable for investigation of linked activity among these systems and the pathogenesis of atherosclerosis. Accordingly, we used ¹⁸F-FDG-PET/CT to test the hypotheses that amygdalar activity is associated with haemopoietic activity and arterial infl ammation, and predicts the development of future cardiovascular disease events.
Methods

Study design and participants
We did two complementary imaging studies: a longitudinal outcomes study to assess the relation between resting amygdalar metabolic activity, atherosclerotic infl ammation, and subsequent cardiovascular events, and a smaller, cross-sectional perceived stress study to assess the relation between psychometric measures of perceived stress, resting amygdalar metabolic activity, and atherosclerotic infl ammation.
Participants were identifi ed from a pool of 6088 patients who underwent ¹⁸F-FDG PET/CT for clinical assessment (mainly for cancer screening) at the Massachusetts General Hospital (Boston, MA, USA) between Jan 1, 2005, and Dec 31, 2008 . Predefi ned inclusion criteria included either absence of previous history of cancer or remission from cancer for at least 1 year before imaging (and throughout the follow-up period), absence of cardiovascular disease or acute or chronic infl ammatory or autoimmune disease at time of imaging, and age older than 30 years. To ensure adequate information for events adjudication, an additional inclusion criterion was the availability of at least three clinical encounter notes in the medical records a minimum of 1 year apart. A full list of inclusion criteria is included in the appendix. All individuals who were included in a previous study 23 of the relation between arterial infl ammation and cardiovascular disease events were included in our study if their scans showed the amygdala. The study protocol was approved by the Partners Human Research Committee. No specifi c informed consent was needed for this study.
Procedures
Two cardiologists (AT and QAT) blinded to PET/CT data used clinical records to adjudicate cardiovascular disease events, which were defi ned, according to the Framingham Heart Study, 24 as coronary death, myocardial infarction, coronary insuffi ciency, angina, cerebrovascular accidents, revascularisation, peripheral artery disease, and heart failure. Two additional and
Research in context
Evidence before the study Chronic stress carries an attributable risk for cardiovascular disease that is on par with other recognised risk factors, such as smoking, increased lipid concentrations, hypertension, and diabetes. Despite the prevalence and potency of this risk factor, little is known about the mechanisms that translate stress into cardiovascular disease events. To assess existing work, we searched PubMed with the terms "psychosocial stress", "arterial infl ammation", "bone marrow", "hematopoietic", "human", and "cardiovascular disease" for articles published in English before June 18, 2016 . Although a link between stress, bonemarrow activity, and arterial infl ammation had been identifi ed in animal studies, this link had not previously been assessed in human beings. Furthermore, we found no studies in which the relation between neural tissue activity and cardiovascular disease events was assessed in either animal models or people.
Added value of this study
Our study provides several novel observations that together defi ne a mechanism linking stress to cardiovascular events. We show for the fi rst time in human beings that resting metabolic activity within the amygdala is signifi cantly associated with the risk of developing cardiovascular disease independently of established cardiovascular risk factors. Furthermore, the link between amygdalar activity and cardiovascular disease events was substantially mediated by arterial infl ammation (which in turn was substantially mediated by upregulated bone-marrow activity). These observations provide new and important insights, specifi cally that the amygdala could be a key structure in the mechanism linking stress to cardiovascular disease events, and that upregulation of haemopoietic tissue activity and increased atherosclerotic infl ammation are additionally implicated in a neural-haemopoietic-arterial axis.
Implications of all the available evidence
Our results provide unique insights into mechanisms translating stress to cardiovascular disease and raise the possibility that alleviation of psychosocial stress could produce benefi ts that extend beyond an improved sense of psychological wellbeing, by improving the atherosclerotic milieu. Eventually, chronic stress could be treated as an important risk factor for cardiovascular disease, one that is routinely screened for and eff ectively managed, similar to other major cardiovascular disease risk factors.
See Online for appendix increasingly stringent subcategories of events were assessed as exploratory endpoints: major adverse cardiovascular events (which excluded angina without evidence of occlusive coronary disease), and atherosclerotic major adverse cardiovascular events (which required identifi cation of potential culprit atherosclerotic plaque in association with the events; appendix).
¹⁸F-FDG was given intravenously at a dose of ~370 MBq after an overnight fast. After tracer injection, individuals sat in a quiet waiting room and PET/CT was done around 1 h later with an integrated scanner (Biograph 64, Siemens Healthcare, Erlangen, Germany [or similar]). Non-gated, non-contrast-enhanced CT (120 keV, ~50 mAs) was done for attenuation correction. Image analyses (appendix) were done by a radiologist (AI) who was blinded to the clinical data and used a dedicated workstation. Analysis of amygdalar activity was based on a validated approach that has shown associations with anxious temperament 19, 25 and clinical manifestations of stress-related disorders. 16 Bone-marrow activity, splenic activity, and arterial infl ammation were measured according to previously validated methods 12, 20 by deriving SUVs from the target tissue (bone marrow, spleen, or aortic and carotid walls) and correcting them for venous blood background activity to calculate target-to-background ratios. Arterial ¹⁸F-FDG uptake is a well validated measure of arterial infl ammation that relates to atherosclerotic macrophages 22 and predicts subsequent cardiovascular disease events. 23 ¹⁸F-FDG uptake in subcutaneous adipose tissue was derived as a control measure of glycolytic activity. Coronary artery calcium score and visceral adipose tissue volume were derived from CT images (appendix).
Perceived stress study
To assess further the role of stress in the associations noted in the longitudinal study, in a separate crosssectional study we tested the hypotheses that perceived stress is associated with resting amygdalar metabolic activity, arterial infl ammation, and infl ammatory biomarkers. 13 individuals with an increased burden of chronic stress (ie, history of post-traumatic stress disorder) were recruited from the community, completed the well validated, ten-item Perceived Stress Scale (PSS-10) 27 and underwent ¹⁸F-FDG PET (Siemens mMR, Erlangen, Germany). Amygdalar activity, C-reactive protein (CRP), and arterial infl ammation were measured (appendix). Further details of the perceived stress study are in the appendix.
Statistical analysis
Continuous variables are listed as mean (SD) or, when not normally distributed, median (IQR). We used Pearson product-moment correlation to assess univariate associations for normally distributed variables, and Spearman correlation coeffi cients for non-normally distributed variables. Cox proportional hazards models were used, with or without the addition of potential confounders as covariates, to calculate hazard ratios (HRs) and 95% CIs. Additionally, we did log-rank tests to generate Kaplan-Meier estimates (and associated curves) of cardiovascular event-free survival, comparing clinical events in patients with higher-versus-lower amygdalar activity. Mediation analysis-which tests a putative causal relation among variables (ie, a path)-was also done to test whether amygdalar activity exerts its eff ect on cardiovascular disease via postulated mediators (bone-marrow activity and arterial Eligible patients were selected on the basis of pre-defi ned criteria. All patients meeting these criteria were included. Image analyses and event adjudication were performed by mutually blinded investigators. 18 
Role of the funding source
There was no funding source for this study. AT, AI, RAPT, and RKP had full access to all study data, and AT had fi nal responsibility for the decision to submit for publication.
Results
Imaging and cardiovascular disease events data were available for 293 people in the longitudinal outcomes study (fi gure 1). Baseline characteristics are listed in table 1. Individuals who developed subsequent cardiovascular events had an increased prevalence of several atherosclerotic risk factors compared with those who did not develop cardiovascular events. Of the atherosclerotic risk factors that were signifi cant on univariate analyses, two remained signifi cantly associated with cardiovascular disease events in multivariate analyses: age (standardised β 0·27; p=0·0003) and smoking (0·22; 0·0028). Furthermore, age and family history of coronary disease were associated with amygdalar activity (appendix). During median follow-up of 3·7 years (IQR 2·7-4·8), 22 individuals experienced 39 cardiovascular disease events. The 22 index events were eight myocardial infarctions, three unstable angina, two peripheral arterial disease, six strokes, one heart failure, and two new onset angina (appendix). Amygdalar activity (ie, amygdala c and amygdala cbl ) robustly predicted the risk of developing a subsequent cardiovascular event (fi gure 2, table 2), yielding adjusted standardised HRs of approximately 1·6 (ie, a 1·6-times increased risk of a cardiovascular event for each increase of one SD in amygdalar signal). However, activity in the background brain structures (cerebral or cerebellar) or control extra-cranial tissue (subcutaneous fat) was not signifi cantly associated with cardiovascular disease (appendix).
Furthermore, the relation between amygdalar activity and cardiovascular disease events remained signifi cant after multivariate adjustments for cardiovascular risk factors, Framingham risk scores, and pre-existing atherosclerotic disease burden (table 2; appendix), and after correction for coronary artery calcium score or visceral adipose tissue volume (appendix). Notably, amygdalar activity generally remained associated with cardiovascular disease in subgroups with or without pre-clinical evidence of atherosclerosis at baseline (as coronary atherosclerotic calcifi cation), subgroups with or without a high burden of coronary atherosclerotic risk factors, and subgroups with or without a previous history of cancer (table 3) .
Full cohort (n=293)
No cardiovascular event (n=271) Cardiovascular event (n=22) p value (event vs no event)
Median age, years (IQR) Data are n (%), unless otherwise specifi ed. The coronary artery calcium score is a measure derived from coronary CT. The presence of calcium in the coronary artery suggests the presence of coronary atherosclerotic disease. *Data for depression and anxiety and for antidepressant drug use were available for 288 participants-268 in the no events group and 20 in the cardiovascular disease events group. Amygdalar activity generally remained associated with cardio vascular events when more stringent defi nitions of events were used (ie, major adverse cardiovascular events and atherosclerotic major adverse cardiovascular events). The associated HRs increased relative to the stringency of the event defi nition (table 4) . Additionally, amygdalar activity seemed to be associated with the timing of the cardiovascular disease event: individuals with higher resting amygdalar activity experienced subsequent cardiovascular disease events sooner than those with lower resting amygdalar activity (appendix).
To further explore the relation between amygdalar activity and cardiovascular disease, we compared outcomes for individuals with high amygdalar activity outcomes for those with low amygdalar activity. We determined the threshold values defi ning high activity by three distinct approaches: receiver operating characteristic analysis, which yielded values with the highest accuracy to identify subsequent cardiovascular disease events; one or more SD above the mean; and as 90th percentile or greater. All remaining individuals were characterised as having low activity.
When the primary amygdalar imaging endpoint was dichotomised into high-activity and low-activity groups, Cox regression analyses yielded signifi cantly increased HRs (table 5) and Kaplan-Meier analyses yielded signifi cant group diff erences (fi gure 3). We noted similar fi ndings when the secondary and post-hoc measures of amygdalar activity were similarly dichotomised (table 5) . Additionally, amygdalar activity remained robustly predictive of cardiovascular disease when several other means of measuring it were used in sensitivity analyses (appendix).
Amygdalar activity correlated with haemopoietic tissue activity, expressed as ¹⁸F-FDG-uptake in the bone marrow and spleen (table 6) , and with arterial ¹⁸F-FDG uptake, a well validated measure of arterial infl ammation. 22, 28 Moreover, measures of haemopoietic activity, especially in bone marrow, were associated with several measures of circulating blood cells, including total white blood cell count and neutrophil and lymphocyte counts (appendix). However, amygdalar activity did not correlate with ¹⁸F-FDG-uptake in control tissue (ie, subcutaneous fat; table 6).
Bone-marrow activity was a signifi cant mediator of the relation between amygdalar activity and arterial infl ammation, accounting for a substantial 46% of the total eff ect. Arterial infl ammation was a signifi cant mediator of the relation between amygdalar activity and cardiovascular disease events, accounting for 39% of the total eff ect. Serial two-mediator analysis supported the hypothesised indirect path of increased amygdalar activity leading to increased bone-marrow activity leading to increased arterial infl ammation leading to cardiovascular disease events (fi gure 4). These results suggest that bone-marrow activity and arterial infl ammation, in series, have an important role in mediation of the association between amygdalar activity and cardiovascular disease events. Finally, when the path implicating bone-marrow activity was excluded, the residual path of increased amygdalar activity leading to increased arterial infl ammation leading to cardiovascular disease events (fi gure 4) was also signifi cant, suggesting that amygdalar activity also infl uences arterial infl ammation and hence cardiovascular events through means other than haemopoiesis. That the mediators account for less than 100% of the total eff ects also suggests that amygdalar activity also aff ects cardiovascular disease events through means other than arterial infl ammation.
In the cross-sectional study, in congruence with the longitudinal study's fi ndings, amygdalar activity strongly correlated with arterial infl ammation (r=0·70, p=0·0083). Perceived stress was associated with amygdalar activity (0·56; 0·0485; fi gure 5A), arterial infl ammation (0·59; 0·0345, fi gure 5B) and CRP (0·83; 0·0210; fi gure 5C). Furthermore, amygdalar activity mediated most of the relation between perceived stress and arterial infl ammation (p<0·05; appendix).
Discussion
Our results show, for the fi rst time in human beings, that resting metabolic activity within the amygdala, a key component of the brain's salience network involved in stress, signifi cantly predicts the development of cardiovascular disease independently of established cardiovascular risk factors. Furthermore, we showed that amygdalar activity is associated with increased haemopoietic activity and increased arterial infl ammation. In the companion cross-sectional study, amygdalar activity was associated with perceived stress. In the longitudinal outcomes study, moreover, the link between amygdalar activity and cardiovascular disease events was substantially mediated by arterial infl ammation (which in turn was substantially mediated by upregulated bone-marrow activity). These fi ndings provide new and important insights, specifi cally that the amygdala could be a key structure in the mechanism linking stress to cardiovascular events, and that upregulation of haemopoietic tissue activity and increased atherosclerotic infl ammation are additionally implicated in a neural-haemopoieticarterial axis.
Psychological stress has long been thought of as an important human malady. Over the past several decades, increasing attention has been paid to the physical manifestations of stress. Despite evidence linking psychological stress and cardiovascular disease, 29 cardiovascular risk management has remained focused on other risk factors, possibly partly as a result of poor understanding of the mechanisms Covariate: pre-existing atherosclerotic disease (CAC score)
Covariate: history of depression or anxiety
Covariate: antidepressant use
We measured amygdalar activity with several diff erent approaches, providing a primary, two secondary, and one post-hoc measure. Amygdalar activity was corrected for background cerebral (c) or cerebellar (cbl) neural tissue activity. Max max is the maximum SUV for the right and left amygdalae. Mean mean is the mean of the mean SUVs in the right and left amygdalae. Mean max is the mean of the maximum SUVs in the right and left amygdalae. Mean L is the mean SUV for the left amygdala. CAC=coronary artery calcium. HR=hazard ratio. SUV=standardised uptake value. *The cardiac risk factors that were entered into this model were each of the standard cardiovascular risk factors that were signifi cantly associated with the development of events on the basis of univariate analysis (table 1) -age, smoking, hypertension, diabetes, dyslipidaemia, and family history-which were entered as cofactors in a stepwise (backward) conditional manner. underlying stress-associated cardiovascular disease. Our study is clinically important because it advances this understanding and suggests targets for novel therapeutic approaches to reduce cardiovascular disease risk. Stress prompts activation of both the sympathetic nervous system and the hypothalamic-pituitaryadrenal axis, leading to increases in circulating catecholamines, glucocorticoids, and (eventually) infl ammatory cytokines. [30] [31] [32] Additionally, stress can increase heart rate and blood pressure via the autonomic nervous system, all of which can contribute to endothelial dysfunction. 33 However, these mechanisms do not entirely explain the link between stress and cardiovascular disease. Work in animals has yielded important new insights into another (and 
Individuals without previous subclinical coronary artery disease (CAC=0)
Per unit change
Individuals with ≥3 coronary risk factors
Individuals with <3 coronary risk factors
Individuals with previous cancer
Individuals without previous cancer
We measured amygdalar activity with several diff erent approaches, providing a primary, two secondary, and one post-hoc measure. Amygdalar activity was corrected for background cerebral (c) or cerebellar (cbl) neural tissue activity. No additional adjustments were included in the subgroup analyses. Coronary risk factors include age older than 55 years, male sex, current smoker, hypertension, diabetes, and dyslipidaemia. Max max is the maximum SUV for the right and left amygdalae. Mean mean is the mean of the mean SUVs in the right and left amygdalae. Mean max is the mean of the maximum SUVs in the right and left amygdalae. Mean L is the mean SUV for the left amygdala. CAC=coronary artery calcium. HR=hazard ratio. SUV=standardised uptake value. 
Cardiovascular disease
We measured amygdalar activity with several diff erent approaches, providing a primary, two secondary, and one post-hoc measure. Amygdalar activity was corrected for background cerebral (c) or cerebellar (cbl) neural tissue activity. Max max is the maximum SUV for the right and left amygdalae. Mean mean is the mean of the mean SUVs in the right and left amygdalae. Mean max is the mean of the maximum SUVs in the right and left amygdalae. Mean L is the mean SUV for the left amygdala. HR=hazard ratio. MACE=major adverse cardiovascular event. AMACE=atherosclerotic major adverse cardiovascular event (requires confi rmed presence of an atherosclerotic culprit lesion). SUV=standardised uptake value. Table 4 : Analysis of neural tissue activity vs events-additional event defi nitions potentially more important) mechanism by which stress might induce cardiovascular disease. Murine studies show that stress leads to mobilisation and release of neutrophils and monocytes, and increases activity of haemopoietic progenitor cells in the bone marrow. 13 Haemopoietic progenitors might accumulate in the circulation and the spleen and are thus poised to potentiate leucocyte supply by establishing extramedullary haemopoiesis. [34] [35] [36] In mice, bone-marrowderived monocytes released in response to variable stress or to stressful events (such as myocardial infarction) migrate to the arterial wall, where they instigate atherosclerotic infl ammation. 11, 13, 37 Results from animal studies 38 point to increased haemopoiesis and arterial infl ammation as important mechanisms in stress. They also prompt two crucial questions that were addressed by our study: is this mechanism relevant to human beings, and how does the brain participate?.
Our results clearly identify the amygdala as a key neural structure associated with future cardiovascular disease events. Previous human imaging studies demonstrated that amygdalar activity is correlated with the infl ammatory response to stress 39 and the presence of pre-existing preclinical atherosclerosis.
14 However, a longitudinal pathogenetic link such as that which we noted, to the best of our knowledge has never been identifi ed. Furthermore, by demonstrating a signifi cant pathway of increased amygdalar activity leading to increased bone-marrow activity leading to increased arterial infl ammation leading to cardiovascular disease event (fi gure 6), our fi ndings are a key addition to the literature. Increased amygdalar activity and its downstream consequences of upregulated haemopoietic and infl ammatory activity could also be implicated in other medical conditions in which infl ammation has an important role.
Our study has several limitations. First, the participants in the outcomes study were identifi ed from a clinical database of patients who had undergone ¹⁸F-FDG PET/CT for clinical indications (mainly cancer screening), thus possibly limiting the generalisability of our fi ndings. However, the association between amygdalar activity and cardiovascular disease events remained robust in the subgroup of individuals who did not have history of cancer, suggesting that this Event-free survival for the primary amygdalar endpoint (max max amygdala c -ie, the maximum standardised uptake value for the right and left amygdalae, corrected for background cerebral tissue activity) are shown. p values were calculated with the log-rank test, and cox regression analyses were done to calculate HRs. HR=hazard ratio.
Number at risk
Low activity High activity potential confounder is not responsible for the main observations of this study. Second, 271 (93%) of 293 individuals in the outcomes study were white. However, in the separate cross-sectional perceived stress substudy, most participants were not white and none had a previous history of cancer (data not shown). In that substudy, the relation between amygdalar activity and arterial infl ammation remained robust, lending support to the fi ndings of the main study. Third, standard questionnaires were not used in the outcomes study, and thus the relation between perceived stress or mental disorder and cardiovascular disease events was not directly assessed. However, the perceived stress substudy showed a relation between perceived stress and both amygdalar activity and arterial infl ammation, thus providing independent validation of the fi ndings. Fourth, a positive mediation analysis, as we report here, is consistent with, but not demonstrative of, causation-particularly when a portion of the data are cross-sectional, as was the case with amygdalar activity, bone-marrow activity, and arterial infl ammation. To infer causation, further longitudinal or interventional studies are needed. Additionally, the pathway from amygdalar activity to cardiovascular disease presented herein does not purport to encompass all possible pathological infl uences on any of its nodes. Candidate infl uences include, among others, sympathetic activity, hormones (eg, neuropeptide Y, GABAergic neuro steroids), and cytokines. Finally, the sample size of the main study was modest and only 22 participants had a cardiovascular disease event. These limitations are substantially counterbalanced by several important innovations, including the unique, simultaneous quantifi cation of arterial, amygdalar, and bone-marrow activity, and their associations with cardiovascular disease events in human beings.
Acitvation of the brain stress network and its downstream consequences, including haemopoietic tissue activation and increased arterial infl ammation, could be targets for therapies designed to interrupt a vicious cycle between stress and cardiovascular events. Our fi ndings should prompt not only further investigation of the mechanisms that regulate this axis, but also studies of how to interrupt pathogenetic transmission along it. One possible future research avenue would be to experimentally induce amygdalar activation (eg, by stressful mental imagery 40 or presentation of fear-related stimuli 16 ), and then examine the acute eff ect on bone-marrow activity and arterial infl ammation. In a more ambitious vein, meditation has been shown to reduce amygdalar activity. 41 In a study of 226 individuals, 42 those randomly assigned to a 12-week stress-reduction course experienced an approximately 50% reduction in cardiovascular disease events compared with individuals who underwent cardiac rehabilitation but not stress management training.
Our fi ndings raise the hypothesis that the benefi ts noted in that stress-reduction study 42 could partly have been due to a therapeutic action on the neuralhaemopoietic-arterial axis described herein. In the future, larger studies will be needed to assess modulation of this axis, which could produce a substantial benefi cial clinical eff ect. Such studies should examine the impact of various stressmanagement strategies (targeting upstream portions of this axis), in addition to pharmacotherapies that target other aspects of this axis. In the meantime, when encountering a patient with a stress syndrome, clinicians could reasonably consider the possibility that alleviation of stress might result in benefi ts to the cardiovascular system. Eventually, chronic stress could . A single-mediator analysis showed that bone-marrow activity was a signifi cant mediator of the relation between amygdalar activity and arterial infl ammation. Another single-mediator analysis showed that arterial infl ammation was a signifi cant mediator of the relation between amygdalar activity and cardiovascular disease events. A serial two-mediator analysis testing the hypothesised indirect path of increased resting amygdalar activity leading to increased bone-marrow activity leading to increased arterial infl ammation leading to cardiovascular disease events (red arrows) was signifi cant. Additionally, excluding the path through bone-marrow activity, the residual path of increased resting amygdalar activity leading to increased arterial infl ammation leading to cardiovascular disease event (blue arrows) was also signifi cant. Amygdalar activity was assessed as the primary measure, max max amygdala c (ie, the maximum standardised uptake value for the right and left amygdalae, corrected for background cerebral tissue activity). Bone-marrow activity was measured by ¹⁸F-FDG uptake in vertebral bone marrow corrected for background uptake in the superior vena cava. Arterial infl ammation was measured by ¹⁸F-FDG uptake in the aortic wall corrected for background uptake in the superior vena cava. In the fi gure, c represents the total eff ect of amygdalar activity on cardiovascular disease events, whereas c' is the residual direct eff ect of amygdalar activity on cardiovascular disease events (independent of mediated eff ects). Standardised regression coeffi cients or log odds ratios are shown; all analyses incorporated age, sex, and baseline coronary artery calcifi cation (as a control for pre-existing atherosclerotic disease burden) as covariates. The appendix contains additional explanation. ¹⁸F-FDG=¹⁸F fl uorodeoxyglucose. *p=0·0073. †p<0·0001. ‡p=0·0044. §p=0·0432. ¶p=0·6409. ||p=0·2196. **p=0·013. be treated as an important risk factor for cardiovascular disease, one that is routinely screened for and eff ectively managed, like other major cardiovascular disease risk factors.
Our study shows, for the fi rst time, a relation between neural tissue activity and subsequent cardiovascular events and suggests that the brain's salience network, bone marrow, and arterial infl ammation together form an axis that could accelerate the development of cardiovascular disease. Furthermore, our fi ndings raise the possibility that eff orts to attenuate psychosocial stress could produce benefi ts that extend beyond an improved sense of psychological wellbeing, and could benefi cially impact the atherosclerotic milieu. Future studies of this neural-haemopoietic-arterial axis might lead to insights into how to further reduce the burden of cardiovascular disease.
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